13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002092021
Total reported value
$605.9M
$605.9M
85 檔
14.4%
During the Q4 2025 filing period, Seven Fleet Capital Management LP (CIK: 0002092021) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $605.9M across 85 reported positions.
During Q4 2025, Seven Fleet Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 42.57% | +20.49% | — | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 5.15% | -0.88% | — | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 4.08% | -1.23% | EXIT | |
| 4 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.57% | — | — | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.55% | +4.99% | — | |
| 6 | LQDA | Liquidia CORP | Stock-Other | 2.13% | +1.13% | — | |
| 7 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.07% | -0.79% | — | |
| 8 | EXEL | Exelixis Inc | Stock-Healthcare | 2.03% | — | — | |
| 9 | ASMB | Assembly Biosciences Inc | Stock-Other | 1.70% | +1.47% | — | |
| 10 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.60% | +0.41% | — | |
| 11 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.42% | -2.38% | EXIT | |
| 12 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.29% | +12.46% | — | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 1.23% | +0.93% | — | |
| 14 | XNCR | Xencor Inc | Stock-Other | 1.14% | +0.98% | — | |
| 15 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.04% | +1.02% | — | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 1.04% | +2.87% | — | |
| 17 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.03% | -0.60% | EXIT | |
| 18 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.99% | — | — | |
| 19 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.93% | — | — | |
| 20 | NUVL | Nuvalent Inc-a | Stock-Other | 0.86% | -0.07% | EXIT | |
| 21 | ASND | Ascendis Pharma A/S | Stock-Other | 0.82% | -0.88% | EXIT | |
| 22 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.80% | — | — | |
| 23 | PCVX | Vaxcyte Inc | Stock-Other | 0.79% | -1.71% | — | |
| 24 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.78% | +1.34% | — | |
| 25 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.74% | -0.05% | — | |
| 26 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.73% | -0.12% | — | |
| 27 | GERN | Geron CORP | Stock-Other | 0.69% | +0.02% | — | |
| 28 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.67% | -0.24% | — | |
| 29 | LONA | Leonabio Inc | Stock-Other | 0.66% | -0.31% | — | |
| 30 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.62% | +0.75% | — | |
| 31 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.61% | -0.15% | — | |
| 32 | ✓ | Zura Bio LTD | Stock-Other | 0.59% | — | — | |
| 33 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.58% | -1.90% | — | |
| 34 | CELC | Celcuity Inc | Stock-Other | 0.56% | +0.06% | — | |
| 35 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.54% | +0.42% | NEW | |
| 36 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.53% | -0.82% | EXIT | |
| 37 | PALI | Palisade Bio Inc | Stock-Other | 0.52% | -0.03% | — | |
| 38 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.50% | +0.40% | NEW | |
| 39 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.47% | +0.79% | — | |
| 40 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 41 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.44% | +0.38% | — | |
| 42 | NKTR | Nektar Therapeutics | Stock-Other | 0.43% | -0.10% | EXIT | |
| 43 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.43% | -0.21% | EXIT | |
| 44 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.42% | -0.26% | — | |
| 45 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.41% | -0.41% | — | |
| 46 | MBX | Mbx Biosciences Inc | Stock-Other | 0.39% | +0.05% | NEW | |
| 47 | EOLS | Evolus Inc | Stock-Other | 0.37% | -0.01% | — | |
| 48 | ZYME | Zymeworks Inc | Stock-Other | 0.37% | — | — | |
| 49 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.31% | -0.23% | — | |
| 50 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.31% | — | — |
According to official SEC Form 13F filings, Seven Fleet Capital Management LP reported a total U.S. public equity portfolio value of $605.9M across 85 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, COGT, SLNOEUR) accounted for 14.4% of total reported equity market value during Q4 2025.
During Q4 2025, Seven Fleet Capital Management LP's top holdings by market value included CGON (42.6%)、COGT (5.2%)、SLNOEUR (4.1%). The largest single position, CGON, represented 42.6% of total portfolio value.
In Q4 2025, Seven Fleet Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.